{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:20:00Z","timestamp":1785831600018,"version":"3.56.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.idc.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T10:26:22Z","timestamp":1596882382000},"page":"539-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Applying the Infectious Diseases Literature to People who Inject Drugs"],"prefix":"10.1016","volume":"34","author":[{"given":"David P.","family":"Serota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A.","family":"Chueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos C.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.idc.2020.06.010_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.15585\/mmwr.mm6810a6","article-title":"Notes from the field: HIV diagnoses among persons who inject drugs - Northeastern Massachusetts, 2015-2018","volume":"68","author":"Cranston","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"10.1016\/j.idc.2020.06.010_bib2","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged <\/=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib3","doi-asserted-by":"crossref","first-page":"ofw157","DOI":"10.1093\/ofid\/ofw157","article-title":"Increasing infectious endocarditis admissions among young people who inject drugs","volume":"3","author":"Wurcel","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/M18-2124","article-title":"Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data","volume":"170","author":"Schranz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2020.06.010_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugalcdep.2016.04.009","article-title":"Nationwide increase in hospitalizations for heroin-related soft tissue infections: associations with structural market conditions","volume":"163","author":"Ciccarone","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.idc.2020.06.010_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa008","article-title":"Bacterial infections associated with substance use disorders, large cohort of United States Hospitals, 2012-2017","author":"McCarthy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.06.010_bib7","article-title":"Long-term outcomes are poor in intravenous drug users following infective endocarditis, even after surgery","author":"Straw","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.06.010_bib8","first-page":"E1","article-title":"New answers for old questions in the treatment of severe infections from injection drug use","volume":"14","author":"Serota","year":"2019","journal-title":"J\u00a0Hosp Med"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib9","doi-asserted-by":"crossref","first-page":"ofy132","DOI":"10.1093\/ofid\/ofy132","article-title":"Infectious diseases physicians' perspectives regarding injection drug use and related infections, United States, 2017","volume":"5","author":"Rapoport","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.06.010_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jhm.2582","article-title":"Perceptions and practices of physicians regarding outpatient parenteral antibiotic therapy in persons who inject drugs","volume":"11","author":"Fanucchi","year":"2016","journal-title":"J\u00a0Hosp Med"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.06.010_bib13","author":"Spellberg"},{"issue":"9","key":"10.1016\/j.idc.2020.06.010_bib14","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \"static vs cidal\": a systemic literature review","volume":"66","author":"Wald-Dickler","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2020.06.010_bib16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/cid\/ciz030","article-title":"Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the GAMES Cohort","volume":"69","author":"Perica","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib17","doi-asserted-by":"crossref","first-page":"e013560","DOI":"10.1136\/bmjopen-2016-013560","article-title":"Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review","volume":"7","author":"Mitchell","year":"2017","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.idc.2020.06.010_bib18","doi-asserted-by":"crossref","first-page":"ofy274","DOI":"10.1093\/ofid\/ofy274","article-title":"Outpatient parenteral therapy for complicated Staphylococcus aureus infections: a snapshot of processes and outcomes in the real world","volume":"5","author":"Townsend","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejim.2013.03.014","article-title":"Outpatient parenteral antibiotic therapy: principles and practice","volume":"24","author":"Seaton","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2020.06.010_bib20","doi-asserted-by":"crossref","first-page":"ofy194","DOI":"10.1093\/ofid\/ofy194","article-title":"Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature","volume":"5","author":"Suzuki","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib21","doi-asserted-by":"crossref","first-page":"ofy056","DOI":"10.1093\/ofid\/ofy056","article-title":"Outcomes according to discharge location for persons who inject drugs receiving outpatient parenteral antimicrobial therapy","volume":"5","author":"D'Couto","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib22","doi-asserted-by":"crossref","first-page":"ofz471","DOI":"10.1093\/ofid\/ofz471","article-title":"Patient experiences with outpatient parenteral antibiotic therapy: results of a patient survey comparing skilled nursing facilities and home infusion","volume":"6","author":"Mansour","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2020.06.010_bib23","doi-asserted-by":"crossref","first-page":"105760","DOI":"10.1016\/j.ypmed.2019.105760","article-title":"Integrated outpatient treatment of opioid use disorder and injection-related infections: a description of a new care model","volume":"128","author":"Fanucchi","year":"2019","journal-title":"Prev Med"},{"issue":"6","key":"10.1016\/j.idc.2020.06.010_bib24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/cid\/ciz654","article-title":"Outpatient parenteral antimicrobial therapy plus buprenorphine for opioid use disorder and severe injection-related infections","volume":"70","author":"Fanucchi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.06.010_bib25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/cid\/ciy722","article-title":"A\u00a09-point risk assessment for patients who inject drugs requiring intravenous antibiotics may allow health systems to focus inpatient resources on those at greatest risk of ongoing drug use","volume":"68","author":"Eaton","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.06.010_bib26","series-title":"Do persons with opioid use disorder and injection-related infections really need prolonged hospitalizations to complete intravenous antibiotic therapy?","author":"Fanucchi","year":"2018"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11606-016-3919-4","article-title":"\"It's been an experience, a life learning experience\": a qualitative study of hospitalized patients with substance use disorders","volume":"32","author":"Velez","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.idc.2020.06.010_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2019.04.008","article-title":"Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: results from a qualitative study","volume":"102","author":"Bearnot","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.12788\/jhm.3100","article-title":"Ethical considerations in the care of hospitalized patients with opioid-use and injection drug-use disorders","volume":"14","author":"Alfandre","year":"2019","journal-title":"J\u00a0Hosp Med"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib30","doi-asserted-by":"crossref","first-page":"ofz289","DOI":"10.1093\/ofid\/ofz289","article-title":"Disparity in quality of infectious disease vs addiction care among patients with injection drug use-associated staphylococcus aureus bacteremia","volume":"6","author":"Serota","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib31","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.2105\/AJPH.2015.302885","article-title":"Leaving the hospital against medical advice among people who use illicit drugs: a systematic review","volume":"105","author":"Ti","year":"2015","journal-title":"Am J Public Health"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib32","doi-asserted-by":"crossref","first-page":"e185220","DOI":"10.1001\/jamanetworkopen.2018.5220","article-title":"Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs","volume":"1","author":"Rodger","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.idc.2020.06.010_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.05.007","article-title":"Addiction consultation services - Linking hospitalized patients to outpatient addiction treatment","volume":"79","author":"Trowbridge","year":"2017","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamainternmed.2017.1489","article-title":"Treating the symptom but not the underlying disease in infective endocarditis: a teachable moment","volume":"177","author":"Serota","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib35","first-page":"69","article-title":"Substance use disorder assessment, diagnosis, and management for patients hospitalized with severe infections due to injection drug use","volume":"13","author":"Jicha","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","article-title":"Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis","volume":"129","author":"Rosenthal","year":"2016","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/cid\/ciy632","article-title":"Many opportunities to record, diagnose, or treat injection drug-related infections are missed: a population-based cohort study of inpatient and emergency department settings","volume":"68","author":"Miller","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-016-3799-7","article-title":"Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction","volume":"32","author":"Wakeman","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2020.06.010_bib39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A\u00a0randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","volume":"69","author":"Willekens","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jac\/dky452","article-title":"Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer","volume":"74","author":"Jorgensen","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.06.010_bib42","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/jac\/dkx153","article-title":"Trimethoprim\/sulfamethoxazole versus vancomycin in the treatment of healthcare\/ventilator-associated MRSA pneumonia: a case-control study","volume":"72","author":"Eliakim-Raz","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"14","key":"10.1016\/j.idc.2020.06.010_bib43","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMc1902096","article-title":"Long-term outcomes of partial oral treatment of endocarditis","volume":"380","author":"Bundgaard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8671","key":"10.1016\/j.idc.2020.06.010_bib44","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(89)91083-0","article-title":"Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin","volume":"2","author":"Dworkin","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.idc.2020.06.010_bib46","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/jac\/dkz122","article-title":"From 'OPAT' to 'COpAT': implications of the OVIVA study for ambulatory management of bone and joint infection","volume":"74","author":"Seaton","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"22","key":"10.1016\/j.idc.2020.06.010_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.15585\/mmwr.mm6722a2","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs - six sites, 2005-2016","volume":"67","author":"Jackson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2020.06.010_bib48","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2020.06.010_bib49","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra-\"shorter is better\"","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2020.06.010_bib50","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/cid\/ciy1134","article-title":"Short-course antibiotic therapy-replacing constantine units with \"shorter is better\"","volume":"69","author":"Wald-Dickler","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijantimicag.2019.01.007","article-title":"Short- versus long-course antibiotics in osteomyelitis: A systematic review and meta-analysis","volume":"53","author":"Huang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"9971","key":"10.1016\/j.idc.2020.06.010_bib52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6\u00a0weeks versus 12\u00a0weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.idc.2020.06.010_bib53","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2019-215116","article-title":"Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial","volume":"78","author":"Gjika","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.idc.2020.06.010_bib54","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/cid\/ciw098","article-title":"Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence","volume":"62","author":"Park","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.06.010_bib55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-109-8-619","article-title":"Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy","volume":"109","author":"Chambers","year":"1988","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-125-12-199612150-00005","article-title":"Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial","volume":"125","author":"Ribera","year":"1996","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib57","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/cid\/ciz804","article-title":"Infectious complications of addiction: a call for a new subspecialty within infectious diseases","volume":"70","author":"Serota","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib58","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","article-title":"Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review","volume":"53","author":"Chastain","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib62","doi-asserted-by":"crossref","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.06.010_bib63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib65","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib67","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \"lineless antibiotics\" for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib68","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib69","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/heartjnl-2015-308589","article-title":"Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis","volume":"102","author":"Anantha Narayanan","year":"2016","journal-title":"Heart"},{"issue":"26","key":"10.1016\/j.idc.2020.06.010_bib70","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1056\/NEJMoa1112843","article-title":"Early surgery versus conventional treatment for infective endocarditis","volume":"366","author":"Kang","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib71","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/ciy1064","article-title":"Drug-use and post-operative mortality following valve surgery for infective endocarditis: a systematic review and meta-analysis","volume":"69","author":"Hall","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.athoracsur.2015.03.019","article-title":"Injection drug use and outcomes after surgical intervention for infective endocarditis","volume":"100","author":"Shrestha","year":"2015","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib73","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.athoracsur.2019.09.004","article-title":"Impact of substance use disorder on midterm mortality after valve surgery for endocarditis","volume":"109","author":"Wurcel","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.semtcvs.2018.07.016","article-title":"Recidivism is the leading cause of death among intravenous drug users who underwent cardiac surgery for infective endocarditis","volume":"31","author":"Nguemeni Tiako","year":"2019","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib75","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib76","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.athoracsur.2018.04.012","article-title":"Surgical management of tricuspid valve infective endocarditis: a systematic review and meta-analysis","volume":"106","author":"Yanagawa","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.idc.2020.06.010_bib77","series-title":"Medications for opioid use disorder following injection drug associated endocarditis","author":"Kimmel","year":"2019"},{"key":"10.1016\/j.idc.2020.06.010_bib78","series-title":"Consensus study report of the national academies of sciences, engineering, medicine","article-title":"National Academies of Sciences Engineering and Medicine (U.S.). Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for opioid use disorder save lives","author":"Mancher","year":"2019"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib79","doi-asserted-by":"crossref","first-page":"ofz089","DOI":"10.1093\/ofid\/ofz089","article-title":"High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis","volume":"6","author":"Leahey","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5492\/wjccm.v1.i1.23","article-title":"Severe sepsis and septic shock in the elderly: an overview","volume":"1","author":"Nasa","year":"2012","journal-title":"World J Crit Care Med"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14787210.2016.1135052","article-title":"Challenges with diagnosing and managing sepsis in older adults","volume":"14","author":"Clifford","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib82","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1503\/cmaj.140816","article-title":"Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone","volume":"187","author":"Antoniou","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.idc.2020.06.010_bib83","doi-asserted-by":"crossref","first-page":"g6196","DOI":"10.1136\/bmj.g6196","article-title":"Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study","volume":"349","author":"Fralick","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.idc.2020.06.010_bib84","doi-asserted-by":"crossref","first-page":"107793","DOI":"10.1016\/j.drugalcdep.2019.107793","article-title":"Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: a systematic review and meta-analysis","volume":"207","author":"Colledge","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20132","key":"10.1016\/j.idc.2020.06.010_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drugalcdep.2011.12.012","article-title":"Prevalence of psychiatric disorders among young injection drug users","volume":"124","author":"Mackesy-Amiti","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib86","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/00952990.2014.940424","article-title":"Prescription opioid misuse and mental health among young injection drug users","volume":"41","author":"Mackesy-Amiti","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib87","doi-asserted-by":"crossref","first-page":"23","DOI":"10.15585\/mmwr.mm6701a5","article-title":"HIV infection and hiv-associated behaviors among persons who inject drugs - 20 cities, United States, 2015","volume":"67","author":"Burnett","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib88","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.idc.2020.06.010_bib89","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.idc.2020.06.010_bib90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12954-019-0345-z","article-title":"Self-care habits among people who inject drugs with skin and soft tissue infections: a qualitative analysis","volume":"16","author":"Gilbert","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.idc.2020.06.010_bib91","doi-asserted-by":"crossref","first-page":"107695","DOI":"10.1016\/j.drugalcdep.2019.107695","article-title":"Self-treatment of skin infections by people who inject drugs","volume":"206","author":"Monteiro","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.idc.2020.06.010_bib92","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2018.06.010","article-title":"Negative experiences of pain and withdrawal create barriers to abscess care for people who inject heroin. A mixed methods analysis","volume":"190","author":"Summers","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11606-008-0859-7","article-title":"Patterns and determinants of inappropriate antibiotic use in injection drug users","volume":"24","author":"Starrels","year":"2009","journal-title":"J\u00a0Gen Intern Med"},{"issue":"6","key":"10.1016\/j.idc.2020.06.010_bib94","doi-asserted-by":"crossref","first-page":"e013823","DOI":"10.1136\/bmjopen-2016-013823","article-title":"Cross-sectional association between ZIP code-level gentrification and homelessness among a large community-based sample of people who inject drugs in 19\u00a0US cities","volume":"7","author":"Linton","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.idc.2020.06.010_bib95","unstructured":"Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs\u2014National HIV Behavioral Surveillance: Injection Drug Use, 20 U.S. Cities, 2015. HIV Surveillance Special Report 18. Revised edition. http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html. Published May 2018. Accessed January 21, 2020."},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib96","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2045125317721662","article-title":"Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature","volume":"7","author":"Meid","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40264-016-0477-y","article-title":"Investigating the additive interaction of QT-prolonging drugs in older people using claims data","volume":"40","author":"Meid","year":"2017","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib98","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib99","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","article-title":"Development of a risk score for QTc-prolongation: the RISQ-PATH study","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JCP.0000000000000758","article-title":"Risk management of hospitalized psychiatric patients taking multiple qtc-prolonging drugs","volume":"37","author":"Vandael","year":"2017","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib101","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","article-title":"Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis","volume":"42","author":"Gorelik","year":"2019","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.idc.2020.06.010_bib102","first-page":"489","article-title":"Methadone and the QTc interval: paucity of clinically significant factors in a retrospective cohort","volume":"11","author":"Bart","year":"2017","journal-title":"J\u00a0Addict Med"},{"issue":"12","key":"10.1016\/j.idc.2020.06.010_bib103","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","article-title":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors","volume":"166","author":"Ehret","year":"2006","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.idc.2020.06.010_bib104","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/pds.1112","article-title":"QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system","volume":"14","author":"Pearson","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib105","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1345\/aph.1G524","article-title":"Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients","volume":"40","author":"Baker","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.idc.2020.06.010_bib106","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.038240","article-title":"Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents","volume":"303","author":"Katchman","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib107","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/cpt.1406","article-title":"Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on QT interval during treatment for opioid use disorder","volume":"106","author":"Schmith","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.idc.2020.06.010_bib108","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A\u00a0thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.06.010_bib109","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.06.010_bib110","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.06.010_bib111","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JCP.0000000000000751","article-title":"Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy","volume":"37","author":"Karkow","year":"2017","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.idc.2020.06.010_bib112","first-page":"263","article-title":"Serotonin syndrome due to co-administration of linezolid and methadone","volume":"25","author":"Mastroianni","year":"2017","journal-title":"Infez Med"},{"issue":"4","key":"10.1016\/j.idc.2020.06.010_bib114","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/bja\/aei210","article-title":"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity","volume":"95","author":"Gillman","year":"2005","journal-title":"Br J Anaesth"},{"issue":"8","key":"10.1016\/j.idc.2020.06.010_bib116","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"20","key":"10.1016\/j.idc.2020.06.010_bib117","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJM197605132942008","article-title":"Rifampin-induced methadone withdrawal","volume":"294","author":"Kreek","year":"1976","journal-title":"N\u00a0Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.idc.2020.06.010_bib118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0376-8716(97)84352-9","article-title":"Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users","volume":"43","author":"Brown","year":"1996","journal-title":"Drug Alcohol Depend"},{"issue":"2\u20133","key":"10.1016\/j.idc.2020.06.010_bib119","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drugalcdep.2011.04.013","article-title":"Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients","volume":"118","author":"McCance-Katz","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.idc.2020.06.010_bib120","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/jac\/dkw024","article-title":"Rifabutin: where do we stand in 2016?","volume":"71","author":"Crabol","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:16:32Z","timestamp":1760195792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0891552020300441"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.06.010","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applying the Infectious Diseases Literature to People who Inject Drugs","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}